Synthon's success in the field of complex generic medicines has been a stimulus for us to start development of our own biopharmaceuticals in 2007. The ambition of our biopharmaceutical business is to be best-in-class or first-in-class with innovative products based on new biological and chemical entities. Our growing portfolio reflects our focus and commitment to bringing medicines to patients with a high unmet medical need, notably in oncology and autoimmune diseases.

As part of the Synthon Group, Synthon Biopharmaceuticals is well-positioned to build on the success, global infrastructure and organization of the financially strong, privately held parent company. This distinguishes our innovative Biopharmaceuticals business from other biotech companies and also allows us to make creative choices and to be flexible and dynamic.

State-of-the-art laboratories

We have built state-of-the-art biopharmaceutical research laboratories and GMP facilities for manufacturing monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) - up to Phase III clinical trials and early launches - both for our own portfolio and to support commercial licensees of our ADC technology. 

read more
Strong scientific knowledge base

Our investment in infrastructure and technology is matched by our investment in people. Since the inception of our innovative business, we have gradually built an organization incorporating all the expertise necessary to bring innovative drug candidates to the market.

read more

Synthon Biopharmaceuticals is a member of several national and international platforms.

read more

Partnering and licensing opportunities

We offer selected external parties access to our linker-drug and conjugation technology and (GMP) manufacturing capabilities for (site-specific) conjugation of their own proprietary monoclonal antibodies.

read more

Press releases
25 Jan 2018

Synthon’s [vic-]trastuzumab duocarmazine (SYD985) granted FDA Fast Track designation for pre-treated HER2-positive metastatic breast cancer

read more
15 Mar 2017

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

read more
22 Sep 2019 - 26 Sep 2019 - Gurneys Resort, Newport, RI, U.S.A.

14th Protein Expression in Animal Cells Conference

The goal of the 14th PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in…

read more
25 Sep 2019 - 27 Sep 2019 - Hotel International, Prague, Czech Republic

BEBPA 12th Annual European Bioassay Conference

BEBPA conferences include 2-3 days of presentations, workshops and round-table discussions on topics of current interest to the analytical…

read more